RE:RE:RE:Nothing like a bit of fear to promote PMN310 science You're probably right that it won't have any effect on the IND evaluation, but that still begs the question how did aducanumab and lecanemab ever pass P1 in the first place? How was brain bleeding not a disqualifying safety condition back during their IND phases?
Because it was expensive? Because the technology for diagnosis is relatively novel? Because it doesn't show up well in mice? Or because they had a strong lobby within the revolving door regulatory approval system?
The consensus answer, within the field, should matter to our promotional strategy. Surely there is a nuanced way to tell shareholders and the public alike that whatever scientific value these relic drugs had is long gone, that the generation of drugs to which PMN 310 belongs is at least a decade past the brain bleeding problem, and so these relics are only still even topical because of systemic issues withing the approval and media spheres. Anyone reading this stuff knows full well how corrupt the system is, you can't not know given the pandemic response, but I believe Promis's promotional strategy can be highly effective while completely skirting the issue.